Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism

Performances de l'h-FABP Pour Identifier dès Les Urgences Les Embolies Pulmonaires d'évolution défavorable

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01326507

Enrollment

165

Registered

2011-03-31

Start date

2009-09-30

Completion date

2011-12-31

Last updated

2017-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Keywords

pulmonary embolism, Heart-type fatty acid-binding protein, cardiac biomarkers, risk stratification

Brief summary

The patients presenting with acute pulmonary embolism and right ventricular dysfunction are at high risk for life-threatening events and must be identified in the emergency department for adequate care and hospital admission. Echocardiography can identify right ventricular dysfunction, but this test is not always available, and echocardiographic criteria of right ventricular dysfunction vary among published studies. The primary purpose of this protocol is to study the prognostic value of a cardiac biomarker, h-FABP (heart-type Fatty Acid-Binding Protein) , to identify in the emergency department the patients presenting with high risk pulmonary embolism. As secondary outcomes, H-FABP results will be compared to other cardiac biomarkers (BNP, troponin) and clinical score performances that have been previously studied to stratify the prognosis of patients with pulmonary embolism in the emergency department.

Interventions

BIOLOGICALDosage de l'h-FABP

Dosage de l'h-FABP

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with acute pulmonary embolism diagnosed in the emergency departement

Exclusion criteria

* patient under guardianship * patient without social insurance * pregnant women * refusal to sign the consent * myocardial infarction in the 10 days before pulmonary embolism

Design outcomes

Primary

Measure	Time frame
number of death by pulmonary embolism	1 month
life-threatening pulmonary embolism (cardiopulmonary arrest, shock, mechanical ventilation)	1 month
recurrent episode of pulmonary embolism	1 month

Secondary

Measure	Time frame
prognostic value of a clinical score (PESI), BNP and troponin in acute pulmonary embolism	1 month

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026